Analyzing Ratios: Apogee Therapeutics Inc (APGE)’s Financial Story Unveiled

Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.

The price of Apogee Therapeutics Inc (NASDAQ: APGE) closed at $37.93 in the last session, down -4.36% from day before closing price of $39.66. In other words, the price has decreased by -$4.36 from its previous closing price. On the day, 0.72 million shares were traded. APGE stock price reached its highest trading level at $39.86 during the session, while it also had its lowest trading level at $37.465.

Ratios:

We take a closer look at APGE’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 15.82 and its Current Ratio is at 15.82. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.01.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, BTIG Research on July 07, 2025, Reiterated its Buy rating but revised its target price to $115 from $100 previously.

On March 13, 2025, Citigroup started tracking the stock assigning a Buy rating and target price of $95.

On November 25, 2024, Canaccord Genuity started tracking the stock assigning a Buy rating and target price of $89.Canaccord Genuity initiated its Buy rating on November 25, 2024, with a $89 target price.

Insider Transactions:

An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jul 02 ’25 when Dambkowski Carl sold 10,090 shares for $45.09 per share. The transaction valued at 454,954 led to the insider holds 238,998 shares of the business.

CARL DAMBKOWSKI bought 22,345 shares of APGE for $988,990 on Jul 02 ’25. On Jun 04 ’25, another insider, Dambkowski Carl, who serves as the Chief Medical Officer of the company, sold 2,725 shares for $36.96 each. As a result, the insider received 100,716 and left with 241,723 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, APGE now has a Market Capitalization of 2211800832 and an Enterprise Value of 1712416896.

Stock Price History:

The Beta on a monthly basis for APGE is 1.41, which has changed by -0.22114992 over the last 52 weeks, in comparison to a change of 0.15366066 over the same period for the S&P500. Over the past 52 weeks, APGE has reached a high of $63.50, while it has fallen to a 52-week low of $26.20. The 50-Day Moving Average of the stock is -5.71%, while the 200-Day Moving Average is calculated to be -9.73%.

Shares Statistics:

According to the various share statistics, APGE traded on average about 895.03K shares per day over the past 3-months and 696480 shares per day over the past 10 days. A total of 46.04M shares are outstanding, with a floating share count of 37.32M. Insiders hold about 37.32% of the company’s shares, while institutions hold 88.21% stake in the company. Shares short for APGE as of 1752537600 were 9192676 with a Short Ratio of 10.27, compared to 1749772800 on 9175746. Therefore, it implies a Short% of Shares Outstanding of 9192676 and a Short% of Float of 33.57.

Dividends & Splits

Against a Trailing Annual Dividend Yield of 0.0

Leave a Reply

Your email address will not be published. Required fields are marked *

DWinneX
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.